Enhanced Liver Fibrosis (ELF) Score Test

Your liver can lose a remarkable amount of healthy tissue to scarring before you feel a single symptom or see anything abnormal on a standard blood panel. By the time routine liver enzymes like ALT and AST rise, the damage is often well advanced. The ELF (Enhanced Liver Fibrosis) score was designed to catch this silent process early, measuring three proteins that your body produces when scar tissue is actively forming in the liver.

This matters because fatty liver disease, now called metabolic dysfunction-associated steatotic liver disease (MASLD), affects roughly one in three adults. Most of them have no idea. The ELF score can tell you whether your liver is quietly progressing toward serious scarring, giving you a window to intervene with weight loss, dietary changes, or medication before the damage becomes irreversible.

What the ELF Score Actually Measures

The ELF score is not a single molecule. It combines three blood proteins into a single number using a proprietary algorithm. Each protein reflects a different aspect of the scarring process happening inside your liver. Hyaluronic acid (HA) is a sugar-based molecule that accumulates when scar tissue builds up and the liver can no longer clear it efficiently. PIIINP (amino-terminal propeptide of type III procollagen) is a fragment released when your liver is actively laying down new collagen, the main structural protein in scar tissue. TIMP-1 (tissue inhibitor of metalloproteinase-1) is a protein that blocks the enzymes your body normally uses to break down scar tissue. When TIMP-1 is elevated, scarring accumulates faster because the cleanup crew is being held back.

These three proteins are produced primarily by hepatic stellate cells, specialized cells inside your liver that normally sit quietly and store vitamin A. When the liver is injured repeatedly by fat buildup, alcohol, or viral infection, these cells transform into scar-producing machines. The ELF score essentially measures how active those machines are.

Fatty Liver Disease and Progression to Cirrhosis

The strongest evidence for the ELF score comes from fatty liver disease. In a large population screening study of over 3,300 participants, an ELF score at or above 9.8 identified people at increased risk of progression to cirrhosis and liver-related clinical events. Among those at risk for fatty liver disease, 12 to 14% screened positive for significant fibrosis. In the general population, the rate was 3.4%. Many of these individuals had completely normal liver enzymes.

The American Diabetes Association now recommends fibrosis screening for all people with type 2 diabetes, a population with 40 to 70% prevalence of fatty liver disease and two to four times the risk of advanced scarring compared to people without diabetes. For this group, an ELF score above 9.8 signals the need for specialist evaluation, and a score above 11.3 suggests the highest risk of the liver losing its ability to function properly.

Alcohol-Related Liver Disease

The ELF score performs well in alcohol-related liver disease. In a cohort of 64 patients followed for over six years, each one-point increase in the ELF score was associated with about a twofold greater risk of liver-related events. At a cutoff of 10.5, the test identified advanced fibrosis with 79% sensitivity and 91% specificity in this population.

Viral Hepatitis

In people with chronic hepatitis B, a study of 170 patients followed for about 3.4 years found that the ELF score predicted liver-related events with strong accuracy. Patients in the lowest ELF range had a 95% lower risk of liver events compared to those in the highest range, even after adjusting for other clinical factors. In HIV/hepatitis C coinfection, the ELF score outperformed both the FIB-4 and APRI scores for predicting fibrosis severity.

Long-Term Outcomes

A landmark UK study followed 457 patients with chronic liver disease for a median of seven years. After adjusting for age, sex, and liver biopsy stage, people in the highest ELF category had dramatically higher rates of liver-related death and complications compared to those in the lowest category. In an Australian cohort of 300 patients followed for about six years, 19.2% of those with ELF scores at or above 9.8 experienced liver-related events, compared to very low rates in those below that threshold.

What this means for you: the ELF score is not just a snapshot of current scarring. It predicts what is likely to happen to your liver over the next five to ten years. That prognostic power is what makes it valuable for someone managing their health proactively, because a rising trend gives you time to change course.

Reference Ranges

The ELF score is a calculated number with no units. Men tend to score slightly higher than women (7.0 to 9.9 for men, 6.6 to 9.3 for women in healthy populations), and scores rise modestly with age. Here are the published risk tiers based on validation studies and current guidelines:

These tiers are drawn from published research. Your lab may use slightly different assay platforms and cutpoints. The most reliable approach is to compare your results within the same lab over time rather than treating any single threshold as absolute.

How the ELF Score Compares to Other Fibrosis Tests

The most common first-line fibrosis screening tool is the FIB-4 score, which is calculated from your age, platelet count, and two liver enzymes (AST and ALT). FIB-4 is free to calculate from standard bloodwork, which is why guidelines recommend it as the starting point. But it uses indirect markers of liver injury and portal hypertension rather than measuring scar tissue biology directly. In a head-to-head comparison, the ELF score achieved an accuracy score of 0.85 versus 0.73 for FIB-4 and 0.66 for the NAFLD Fibrosis Score. More importantly, ELF produced far fewer false alarms: 11% false positive rate compared to 35% for FIB-4.

Transient elastography (FibroScan) measures liver stiffness using sound waves and generally has slightly higher accuracy than ELF, particularly for advanced fibrosis. However, FibroScan fails in 5 to 20% of patients with obesity, ascites, or narrow rib spacing, while the ELF score works from a standard blood draw with over 95% applicability. The recommended approach in most guidelines is to use FIB-4 first, then ELF for indeterminate cases, and FibroScan for confirmation when needed.

When Results Can Be Misleading

The ELF score has low biological variability, with a within-person coefficient of variation of just 3.2%. That means it is unusually stable for a blood test. But certain conditions can push the score up or down in ways that do not reflect actual liver scarring, and you should be aware of them.

• Acute illness or infection: Sepsis, acute hepatitis, and systemic inflammatory conditions can temporarily spike hyaluronic acid and PIIINP (two of the three ELF components), producing a falsely elevated score. Wait until you have fully recovered before testing.
• Conditions causing scarring outside the liver: Lung fibrosis and other conditions that increase collagen turnover throughout the body can raise ELF components independently of liver scarring. If you have a known fibrotic condition in another organ, discuss this with whoever interprets your results.
• Previous stomach surgery: Gastrectomy increases hyaluronic acid levels by impairing the liver's ability to clear it, which can push the ELF score up without any change in actual liver fibrosis.
• Hemolysis (blood sample breakdown): If your blood sample breaks down during collection or transport, PIIINP can drop by 21 to 40%, which would lower your ELF score by 2 to 4% and potentially mask real scarring.

Age and sex also influence the score. Afternoon draws tend to produce slightly higher values than morning draws (scores of 6.7 to 9.9 in the afternoon vs. 6.6 to 9.5 in the morning), though the difference is small enough that it rarely changes the clinical interpretation.

Tracking Your Trend

A single ELF score gives you useful information, but serial tracking is where the real value lies. Because the test has such low biological variability (3.2%), a change greater than about 10% between two readings is very likely to reflect a real shift in your liver's scarring activity rather than normal fluctuation. This means you can use the ELF score to measure whether weight loss, dietary changes, or medication is actually working to reverse or halt fibrosis.

In a study of patients tracked for up to 96 weeks, the median per-person variation in ELF scores was only about 3% at 12 weeks and 4% at 96 weeks. That kind of stability makes the ELF score a reliable trend marker. For practical purposes: get a baseline, retest in three to six months if you are actively making changes, and monitor at least annually thereafter. If your score is in the advanced range (9.8 or above), retesting every six months is reasonable to track your trajectory.

Samples are also remarkably durable. Cryopreserved specimens maintain diagnostic accuracy for up to 20 to 25 years, and multiple freeze-thaw cycles do not degrade the result. This means you can trust comparisons between readings taken months or years apart, as long as you use the same lab.